Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy
Clinical and Experimental Rheumatology, Volume 31, No. 3, Year 2013
Notification
URL copied to clipboard!
Description
Objectives: The objective of this paper is to assess if disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating adiponectin and resistin levels in ankylosing spondylitis (AS) patients undergoing TNF-a antagonist therapy. Methods: We investigated adiponectin and resistin serum concentrations in a series of 29 non-diabetic AS patients without history of cardiovascular (CV) events that were treated with the TNF-a antagonist infliximab, immediately prior to an infliximab infusion. Adipokine levels were also determined immediately after administration of an infliximab dose. Results: A significant correlation between adiponectin concentrations and insulin sensitivity (QUICKI at the time of the study) was seen (r=0.384; p=0.05). Also, a marginally significant negative correlation between adiponectin serum levels and the body mass index was observed (r=-0.367; p=0.07). Circulating adiponectin and resistin concentrations did not correlate with disease duration, erythrocyte sedimentation rate, C-reactive protein, BASDAI or VAS at the time of the study. However, AS patients with hip involvement or synovitis and/or enthesitis in other peripheral joints had higher adiponectin concentrations than those who did not have these complications (p-value for both comparisons =0.01). Adiponectin and resistin levels did not change upon infliximab administration. Conclusions: The present study shows that in non-diabetic patients with AS on treatment with infliximab adiponectin and resistin serum levels do not correlate with disease activity. Nevertheless, adiponectin concentration correlates with insulin sensitivity. This finding raises the possibility that low circulating adiponectin concentrations may be involved in the pathogenesis of the CV disease in AS. © CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2013.
Authors & Co-Authors
Miranda-Filloy, José Alberto
Spain, Lugo
Complejo Hospitalario Xeral Calde
López-Mejías, Raquel
Unknown Affiliation
Genre, Fernanda
Unknown Affiliation
Carnero-López, Beatriz
Spain, Ponferrada
Hospital el Bierzo
González-Juanatey, Carlos
Spain, Lugo
Complejo Hospitalario Xeral Calde
Blanco-Alonso, Ricardo
Unknown Affiliation
Llorca-Díaz, Javier Francisco
Spain, Madrid
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
González-Gay, Miguel Ángel
Unknown Affiliation
Statistics
Citations: 22
Authors: 8
Affiliations: 4
Identifiers
ISSN:
1593098X
Research Areas
Noncommunicable Diseases